NATHBIOGEN — Nath Bio-Genes (I) Share Price
Last trade - 00:00- IN₹2.61bn
- IN₹3.24bn
- IN₹4.45bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.38 | ||
| Price to Tang. Book | 0.39 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.53 | ||
| EV to EBITDA | 5.95 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 7.18% | ||
| Return on Equity | 5.53% | ||
| Operating Margin | 10.3% | ||
Financial Summary
| Year End 31st Mar | Unit | 2022 | 2023 | 2024 | 2025 | 2026 | 2027E | 2028E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 2,783.62 | 3,013.64 | 3,326.25 | 3,649.08 | 4,451.02 | n/a | n/a | 7.67% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | +3.76 | +7.54 | -7.28 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Nath Bio-Genes (India) Limited is an India-based company engaged in the business of production, processing, and marketing of hybrid and genetically modified (GM) Seeds. The Company has a product range of field crops, vegetable crops and plant nutrient supplements. The major processing plants are situated at Aurangabad (MS), and Munipalli, Nizamabad (TG). Its segments include Agricultural Activities (Seed Production) and Trading Activities. The Company's product categories include oilseeds and fiber, field crops, vegetables, and plant nutrition. Its fiber and oil seeds include cotton and mustard. The Company's vegetable crop range includes chili, okra, tomato, bottle gourd, bitter gourd, cucumber, coriander, pumpkin, and others. Its field crops include corn, jowar, hybrid paddy, research paddy and wheat. Its plant nutrition products include WINPro GOLii, WINall and Win Chin Win. The Company's forage products include NUTRIMAX and NUTRIMAX GOLD.
Directors
- Satish Kagliwal MDR
- Dhiraj Rathi CCO (30)
- Jeevanlata Kagliwal EDR (77)
- Vadla Nagabhushanam IND (67)
- Madhukar Deshpande IND (68)
- Hitesh Purohit IND (62)
- Amol Gupta CFO
- Akash Kagliwal NED (46)
- Last Annual
- March 31st, 2026
- Last Interim
- June 30th, 2026
- Incorporated
- July 14th, 1993
- Public Since
- January 28th, 2014
- No. of Shareholders
- 33,542
- No. of Employees
- 452
- Sector
- Food & Tobacco
- Industry
- Consumer Defensives
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 19,004,000
- Address
- NATH HOUSE NATH ROAD, MUMBAI, 400020
- Web
- https://nathbiogenes.com/
- Phone
- +91 2222871001
- Auditors
- Gautam N Associates
Latest News for NATHBIOGEN
Upcoming Events for NATHBIOGEN
Q2 2027 Nath Bio-Genes (I) Ltd Earnings Release
Q3 2027 Nath Bio-Genes (I) Ltd Earnings Release
Q4 2027 Nath Bio-Genes (I) Ltd Earnings Release
Similar to NATHBIOGEN
ADF Foods
National Stock Exchange of India
Agri-Tech (India)
National Stock Exchange of India
Ajooni Biotech
National Stock Exchange of India
Amir Chand Jagdish Kumar (Exports)
National Stock Exchange of India
Andrew Yule & Co
National Stock Exchange of India
FAQ
As of Today at 21:16 UTC, shares in Nath Bio-Genes (I) are trading at IN₹137.43. This share price information is delayed by 15 minutes.
Shares in Nath Bio-Genes (I) last closed at IN₹137.43 and the price had moved by -17.62% over the past 365 days. In terms of relative price strength the Nath Bio-Genes (I) share price has underperformed the S&P BSE 100 Index by -16.59% over the past year.
The overall consensus recommendation for Nath Bio-Genes (I) is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Nath Bio-Genes (I) dividend yield is 1.46% based on the trailing twelve month period.
Last year, Nath Bio-Genes (I) paid a total dividend of IN₹2.00, and it currently has a trailing dividend yield of 1.46%. We do not have any data on when Nath Bio-Genes (I) is to next pay dividends.
We do not have data on when Nath Bio-Genes (I) is to next pay dividends. The historic dividend yield on Nath Bio-Genes (I) shares is currently 1.46%.
To buy shares in Nath Bio-Genes (I) you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of IN₹137.43, shares in Nath Bio-Genes (I) had a market capitalisation of IN₹2.61bn.
Here are the trading details for Nath Bio-Genes (I):
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: NATHBIOGEN
Based on an overall assessment of its quality, value and momentum Nath Bio-Genes (I) is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Nath Bio-Genes (I). Over the past six months, its share price has underperformed the S&P BSE 100 Index by -23.18%.
As of the last closing price of IN₹137.43, shares in Nath Bio-Genes (I) were trading -10.81% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Nath Bio-Genes (I) PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹137.43.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Nath Bio-Genes (I)'s management team is headed by:
- Satish Kagliwal - MDR
- Dhiraj Rathi - CCO
- Jeevanlata Kagliwal - EDR
- Vadla Nagabhushanam - IND
- Madhukar Deshpande - IND
- Hitesh Purohit - IND
- Amol Gupta - CFO
- Akash Kagliwal - NED